de.mpg.escidoc.pubman.appbase.FacesBean
Deutsch
 
Hilfe Wegweiser Impressum Kontakt Einloggen
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT

Freigegeben

Zeitschriftenartikel

CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid

MPG-Autoren
http://pubman.mpdl.mpg.de/cone/persons/resource/persons50519

Schjeide,  B. M.
Neuropsychiatric Genetics (Lars Bertram), Dept. of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society;

http://pubman.mpdl.mpg.de/cone/persons/resource/persons50098

Bertram,  L.
Neuropsychiatric Genetics (Lars Bertram), Dept. of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society;

Externe Ressourcen
Es sind keine Externen Ressourcen verfügbar
Volltexte (frei zugänglich)

Giedraitis.pdf
(beliebiger Volltext), 232KB

Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Giedraitis, V., Glaser, A., Sarajarvi, T., Brundin, R., Gunnarsson, M. D., Schjeide, B. M., et al. (2010). CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid. Neuroscience Letters, 469(2), 265-267. doi:10.1016/j.neulett.2009.12.011.


Zitierlink: http://hdl.handle.net/11858/00-001M-0000-0010-7C0E-3
Zusammenfassung
Recently, the P86L alteration in CALHM1 (calcium homeostasis modulator-1) was reported to be associated with Alzheimer's disease (AD). Moreover, the risk allele increased amyloid-beta (A beta) levels in conditioned media from cultured cells. Therefore, we hypothesized that CALHM1 P86L may modulate A beta or tau levels in cerebrospinal fluid (CSF). Nearly 200 individuals with AD or other cognitive disorders were included for CSF analysis and CALHM1 genotyping. No significant differences in CSF levels of A beta 42, tau or phospho-tau were found across the various CALHM1 genotypes. In conclusion, we found no evidence that CALHM1 P86L is associated with altered CSF levels of the investigated AD biomarkers.